EUCTR2018-003630-33-GB进行中(未招募)1 期
Spironolactone for Adult Female Acne: A pragmatic multicentre double-blind randomised superiority trial to investigate the clinical and cost-effectiveness of spironolactone for moderate or severe persistent acne in women - Spironolactone for Adult Female Acne
niversity of Southampton0 个研究点目标入组 434 人开始时间: 2019年11月8日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中(未招募)
- 发起方
- 入组人数
- 434
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •- Women aged 18 years or over
- •- Facial acne, symptoms present since at least 6 months
- •- Acne of sufficient severity to warrant treatment with oral antibiotics, as judged by the study clinician
- •- Women of childbearing potential at risk of pregnancy must be willing to use their usual hormonal or barrier method of contraception for the first 6 months of the study
- •- Willing to be randomised to either study group
- •- Willing and able to give informed consent
- •- Sufficient English to carry out primary outcome Acne-QoL (which has not been validated in other languages)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 433
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 1
排除标准
- •- Serum potassium above the upper limit of the reference range for the laboratory processing the test (measured at the baseline clinic visit)
- •- eGFR below 60 ml/min/1.73m2
- •- Hereditary problems of galactose intolerance, lactase deficiency or glucose-galactose malabsorption
- •- Acne grade 0-1 using the Investigator’s Global Assessment (i.e. clear or almost clear)
- •- Currently taking potassium-sparing diuretic, ACE inhibitor, angiotensin II receptor blocker or digoxin
- •- Started, stopped or changed long-term (lasting more than 2 weeks) hormonal contraception, co-cyprindiol or other hormonal treatment within the past 3 months
- •- Planning to start, stop or change long-term hormonal contraception, co-cyprindiol or other hormonal treatment within the next 3 months
- •- Pregnant/breastfeeding
- •- Intending to become pregnant in the next 6 months
- •- Androgen-secreting adrenal or ovarian tumour
- •- Cushing’s syndrome
- •- Congenital adrenal hyperplasia
- •- Oral antibiotic treatment (lasting longer than a week) for acne within the past month
- •- Oral isotretinoin treatment within the past 6 months
研究者
相似试验
已完成
3 期
Spironolactone for adult female acneAcneISRCTN12892056niversity of Southampton410
尚未招募
4 期
Evaluation of hormonal acne in adult women and its treatment with two different therapies.I01.800acneRBR-7ddb5sIFESP-EPM
已完成
2 期
A single-blind randomised controlled trial of topical Kanuka honey for the treatment of AcneSkin - Dermatological conditionsAcneACTRN12614000003673Honeylab Ltd138
已完成
2 期
Clinical study on Anti-acne spot oil in pimplesCTRI/2022/07/044013amaskar Ayurved Private Limited30
已完成
2 期
Efficacy and safety of oral spironolactone combined with 3% topical minoxidil for the treatment of female pattern hair loss in premenopausal womeFemale pattern hair loss (severityLudwig scale 1-2 )female pattern hair lossalopecia in womenandrogenetic AlopeciaalopeciaTCTR20220613005Srinakharinwirot university43
